FDA Approvals, Stock Price Movements, and Study Results - Research Report on Pfizer, Celgene, Merck, Quest Diagnostics, and Pharmacyclics Editor Note: For more information about this release, please scroll to bottom. PR Newswire NEW YORK, November 21, 2013 NEW YORK, November 21, 2013 /PRNewswire/ -- Today, Analysts' Corner announced new research reports highlighting Pfizer Inc. (NYSE: PFE), Celgene Corporation (NASDAQ: CELG), Merck & Co., Inc. (NYSE: MRK), Quest Diagnostics Inc. (NYSE: DGX) and Pharmacyclics, Inc. (NASDAQ: PCYC). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Pfizer Inc. Research Report On November 18, 2013, Pfizer Inc. (Pfizer) announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for XELJANZ (tofacitinib citrate) to include additional Patient-Reported Outcomes (PRO) data in the label. According to Pfizer, these additional data show improvement in patients receiving XELJANZ based on health-related outcome measures reported by patients, including vitality, role emotional, physical function, bodily pain, social function, mental health, role physical and general health, which are the eight domains of the Medical Outcomes Study Short-Form (36-Item) Health Survey (SF-36). Dr. Steven Romano, Senior Vice President and Head of the Medicines Development Group for Pfizer Specialty Care, said, "The patient-reported outcomes data show the impact that XELJANZ can have on the daily lives of patients with RA, based on physical, mental and emotional measures. Following the FDA approval of XELJANZ in November 2012, we are pleased with the agency's decision to approve this sNDA and add to the growing body of knowledge about XELJANZ as an additional treatment option for patients with RA." The Full Research Report on Pfizer Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/d702_PFE -- Celgene Corporation Research Report On November 18, 2013, Celgene Corporation's (Celgene) stock rose 1.24%, ending the day at $152.98. Over the previous three trading sessions, shares of Celgene gained 2.48% compared to the Nasdaq Composite which declined 0.42% during the same period. The Full Research Report on Celgene Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/7f47_CELG -- Merck & Co., Inc. Research Report On November 18, 2013, Merck & Co., Inc. (Merck) announced that its New Drug Application (NDA) for an investigational intravenous (IV) solution formulation of the Company's antifungal agent, NOXAFIL (posaconazole) has been accepted for priority review by the U.S. Food and Drug Administration (FDA). According to the Company, priority review designation is assigned to application for drugs that, if approved, would provide significant improvements in the safety and effectiveness of the treatment, diagnosis, or prevention of serious conditions. In addition, Merck informed that it has filed a marketing authorization application for NOXAFIL IV solution with the European Medicines Agency (EMA) and plans to seek regulatory approval for the IV formulation in other countries around the world. The Full Research Report on Merck & Co., Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/430d_MRK -- Quest Diagnostics Inc. Research Report On November 18, 2013, Quest Diagnostics Inc. (Quest Diagnostics) released the results of a landmark analysis of workplace drug test. According to the Company, the Drug Testing Index (DTI) examined more than 125 million urine drug tests performed by the Company's forensic toxicology laboratories across the United States as a service for government and private employers between 1988 and 2012. The index reported the percentage of results that tested positive for the presence of a drug or its metabolite, an adulterant or that involved a specimen that was deemed to be unacceptable for testing (positivity). The key findings from the analysis released by the Company suggest that: the positivity rate for the combined U.S. workforce declined 74% from 13.6% in 1988 to 3.5% in 2012; the positivity rate for the federally-mandated safety sensitive workforce declined by 38% from 2.6% in 1992 to 1.6% in 2012; and the positivity rate for the U.S. general workforce declined by 60% from 10.3% in 1992 to 4.1% in 2012. The Full Research Report on Quest Diagnostics Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/05ba_DGX -- Pharmacyclics, Inc. Research Report On November 13, 2013, Pharmacyclics Inc. (Pharmacyclics) announced that the U.S. Food and Drug Administration (FDA) has approved IMBRUVICA (ibrutinib) as a single agent for the treatments of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. According to the Company, IMBRUVICA is a new agent that inhibits the function of Bruton's tyrosine kinase (BTK), a key signaling molecule of the B-cell receptor signaling complex that plays an important role in the survival of malignant B cells. IMBRUVICA blocks signals that stimulate malignant B cells to grow and divide uncontrollably. Pharmacyclics added that IMBRUVICA is one of the first treatments to receive FDA approval via the Breakthrough Therapy Designation pathway and is commercially available now. The Full Research Report on Pharmacyclics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/df74_PCYC ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. AnalystsCorner.com SOURCE Analysts' Corner Contact: Joe Thomas; +1-310-496-8071 (North America)
FDA Approvals, Stock Price Movements, and Study Results - Research Report on Pfizer, Celgene, Merck, Quest Diagnostics, and
Press spacebar to pause and continue. Press esc to stop.